PAX Advanced Therapies

PAX ADVANCED THERAPIES / NEWS

Advancing the Conversation

Stay informed about company developments, technology updates, scientific insights, and future initiatives.

01 / NEWS

News & Publications

01

Company News

Announcements and milestones.

02

Scientific Updates

Research developments and educational content.

03

Industry Insights

Trends shaping regenerative medicine and biotechnology.

04

Events & Presentations

Conferences, meetings, and speaking engagements.

Company announcements and publications will be added here as they become available.

02 / PUBLICATIONS

Impactful Journal Articles

A selection of peer-reviewed publications informing the scientific foundation of PBMC-based regenerative therapies and point-of-care cell concentration technologies.

01Cytotherapy · 2015

Spaltro G, et al. Characterization of the Pall Celeris system as a point-of-care device for therapeutic angiogenesis. Cytotherapy. 2015;17:1302–1313.

02Journal of Clinical Medicine · 2024

Rehak L, et al. The immune-centric revolution translated into clinical application: peripheral blood mononuclear cell (PBMNC) therapy in diabetic patients with no-option critical limb-threatening ischemia (NO-CLTI)—rationale and meta-analysis of observational studies. Journal of Clinical Medicine. 2024;13(23):7230.

DOI: 10.3390/jcm13237230 ↗via pmc.ncbi.nlm.nih
03Journal of Clinical Medicine · 2021

Scatena A, et al. Autologous peripheral blood mononuclear cells for limb salvage in diabetic foot patients with no-option critical limb ischemia. Journal of Clinical Medicine. 2021;10(10):2213.

04Cardiovascular Diabetology · 2022

Panunzi A, et al. Results of a prospective observational study of autologous peripheral blood mononuclear cell therapy for no-option critical limb-threatening ischemia and severe diabetic foot ulcers. Cardiovascular Diabetology. 2022;21:196.

05Acta Diabetologica · 2026

Meloni M, et al. Long-term outcomes of autologous cell therapy in patients with ischaemic diabetic foot ulcers and no-option chronic limb threatening ischaemia. Acta Diabetologica. 2026;63:1447–1457.

06Tissue Engineering Part C: Methods · 2015

De Angelis B, et al. Limb rescue: a new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers. Tissue Engineering Part C: Methods. 2015;21:423–435.

DOI: 10.1089/ten.tec.2014.0245 ↗via pubmed.ncbi.nlm.nih
07Acta Diabetologica · 2025

Meloni M, et al. Predictive factors of major amputation in patients with diabetic foot ulcers treated by peripheral blood mononuclear cells. Acta Diabetologica. 2025;62:1907–1913.

08Heliyon · 2023

Scala P, et al. Contribution of peripheral blood mononuclear cells isolated by advanced filtration system to myogenesis of human bone marrow mesenchymal stem cells co-cultured with myoblasts. Heliyon. 2023;9(6):e17141.

09Frontiers in Bioengineering and Biotechnology · 2023

Scala P, et al. Peripheral blood mononuclear cells contribute to myogenesis in a 3D bioengineered system of bone marrow mesenchymal stem cells and myoblasts. Frontiers in Bioengineering and Biotechnology. 2023;10:1075715.

DOI links resolve to the publisher record. Listings are provided for educational reference and do not constitute endorsement by PAX Advanced Therapies.